| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return | vs S&P 500 ⓘ |
|---|---|---|---|---|---|---|
|
AVBP
ArriVent BioPharma, Inc.
|
Aug 13, 2026 | BUY |
Strong Buy
+35.3% avg upside
15 analysts
|
$43.00
36.59% Upside
|
+0.0% | · |
|
TSE:EPRX
Eupraxia Pharmaceuticals
|
Aug 12, 2026 | BUY |
Strong Buy
+144.4% avg upside
9 analysts
|
$22.31
145.53% Upside
|
· | · |
|
IMUX
Immunic
|
Aug 12, 2026 | BUY |
Strong Buy
+144.1% avg upside
21 analysts
|
$56.00
251.62% Upside
|
+3.3% | · |
|
ORKA
Oruka Therapeutics
|
Aug 11, 2026 | BUY |
Strong Buy
+17.8% avg upside
16 analysts
|
$175.00
62.89% Upside
|
+0.0% | · |
|
OLMA
Olema Pharmaceuticals
|
Aug 11, 2026 | BUY |
Strong Buy
+255.3% avg upside
16 analysts
|
$24.00
129.92% Upside
|
+0.3% | · |
|
DMRA
Damora Therapeutics
|
Aug 11, 2026 | BUY |
Strong Buy
-6.8% avg upside
20 analysts
|
$45.00
45.06% Upside
|
· | · |
|
SYRE
Spyre Therapeutics
|
Aug 11, 2026 | BUY |
Strong Buy
-9.7% avg upside
23 analysts
|
$129.00
23.87% Upside
|
-0.9% | · |
|
COGT
Cogent Biosciences
|
Aug 10, 2026 | BUY |
Strong Buy
-4.5% avg upside
26 analysts
|
$55.00
41.07% Upside
|
-10.2% | · |
|
ELVN
Enliven Therapeutics
|
Aug 08, 2026 | BUY |
Strong Buy
-0.9% avg upside
14 analysts
|
$70.00
20.92% Upside
|
-2.3% | · |
|
IMVT
Immunovant
|
Aug 07, 2026 | BUY |
Strong Buy
-5.1% avg upside
24 analysts
|
$53.00
24.35% Upside
|
+6.4% | · |
|
CLDX
Celldex
|
Aug 07, 2026 | BUY |
Strong Buy
-8.3% avg upside
28 analysts
|
$56.00
24.71% Upside
|
-0.0% | · |
|
CGON
CG Oncology, Inc.
|
Aug 07, 2026 | BUY |
Strong Buy
+11.6% avg upside
17 analysts
|
$108.00
40.37% Upside
|
+1.8% | · |
|
ALXO
ALX Oncology Holdings
|
Aug 06, 2026 | HOLD |
Strong Buy
+802.1% avg upside
11 analysts
|
— | -5.7% | · |
|
IFRX
InflaRx
|
Aug 06, 2026 | BUY |
Strong Buy
+344.7% avg upside
11 analysts
|
$5.00
148.78% Upside
|
+16.9% | · |
|
OKUR
OnKure Therapeutics
|
Aug 05, 2026 | BUY |
Buy
+499.2% avg upside
13 analysts
|
$16.00
307.04% Upside
|
-6.2% | · |
|
PVLA
Palvella Therapeutics
|
Aug 05, 2026 | BUY |
Strong Buy
+8.9% avg upside
27 analysts
|
$236.00
52.22% Upside
|
+0.5% | · |
|
QNCX
Quince Therapeutics
|
Jul 30, 2026 | BUY |
Buy
+578.1% avg upside
16 analysts
|
$99.00
216.73% Upside
|
+31.1% | · |
|
TCRX
TScan Therapeutics
|
Jul 29, 2026 | BUY |
Strong Buy
+1003.4% avg upside
12 analysts
|
$6.00
676.21% Upside
|
+2.7% | · |
|
DBVT
DBV Technologies SA - American
|
Jul 17, 2026 | BUY |
Strong Buy
+69.9% avg upside
15 analysts
|
$45.00
218.30% Upside
|
-4.6% | · |
|
ABVX
Abivax SA Sponsored ADR
|
Jun 30, 2026 | BUY |
Strong Buy
+6.7% avg upside
15 analysts
|
$170.00
35.40% Upside
|
-8.9% | · |
|
PYXS
Pyxis Oncology
|
May 23, 2026 | BUY |
Strong Buy
+146.7% avg upside
14 analysts
|
$6.00
88.70% Upside
|
+84.7% | · |
|
GYRE
Gyre Therapeutics
|
Aug 09, 2023 | HOLD |
Strong Buy
+209.6% avg upside
15 analysts
|
— | +103.9% | · |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.